Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 70/100

Insmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 2018

Tuesday, October 23, 2018 2 min read
Key Takeaway: Insmed Incorporated has announced the release of its third quarter 2018 financial results, scheduled for October 30, 2018. The company will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Interested parties can participate via phone or listen to a live webcast on Insmed's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is focused on addressing unmet needs in rare diseases.
  • The upcoming conference call will provide important financial updates.
  • Insmed's product ARIKAYCE is approved for treating a rare lung disease.

Full Press Release Details

BRIDGEWATER, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its third quarter 2018 financial results on Tuesday, October 30, 2018.
Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, October 30, 2018 to discuss the financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (844) 707-0669 (domestic) or (703) 639-1223 (international) and referencing conference ID number 2556408. The call will also be webcast live on the company's website atwww.insmed.com.
A replay of the conference call will be accessible approximately two hours after its completion through November 6, 2018 by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) and referencing conference ID number 2556408. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website atwww.insmed.com.

AboutInsmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE®(amikacin liposome inhalation suspension), which is approved in the United States for the treatment ofMycobacterium aviumcomplex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visitwww.insmed.com.
Contact:Blaine DavisInsmed Incorporated(908) 947-2841blaine.davis@insmed.com

Frequently Asked Questions

When will Insmed release its Q3 2018 financial results?

Insmed will release its Q3 2018 financial results on October 30, 2018.

What time is the Insmed conference call scheduled?

The conference call is scheduled for 8:30 a.m. ET on October 30, 2018.

How can I participate in the Insmed conference call?

Participants can join by dialing (844) 707-0669 for domestic calls or (703) 639-1223 for international calls.

Where can I find the webcast of the conference call?

The live webcast will be available on Insmed's website at www.insmed.com.

What is Insmed's first commercial product?

Insmed's first commercial product is ARIKAYCE, approved for treating MAC lung disease.

Tags: INSM Viatris Investor Conferences Healthcare Insmed Q3 2018 financial results conference call ARIKAYCE
Last updated: Oct 23, 2018